https://doi.org/10.4081/vl.2026.15920
Objective and subjective effects of a nutraceutical fixed combination in patients with symptoms suggestive of early chronic venous disease: a prospective observational pilot study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 2 September 2026
Early chronic venous disease may significantly impair quality of life even in the absence of overt varicose disease, and effective conservative strategies are needed to relieve symptoms and possibly slow disease progression.
This prospective observational pilot study evaluated the effectiveness and tolerability of a nutraceutical fixed combination with venotropic, anti-inflammatory and draining activity in adults with symptoms suggestive of early-stage chronic venous disease (CEAP C0s-C1s). Sixty patients aged 35-70 years were enrolled, and 40 completed the 90-day follow-up; the 33.3% drop-out/non-completer rate is explicitly reported as a major real-world limitation. Participants received one tablet daily containing micronized flavonoids (μsMIN® Plus; 570 mg, including diosmin 450 mg), Boswellia serrata (Bospure®), bromelain (Bromeyal®), hesperidin, Melilotus officinalis, pineapple extract, and vitamin C. The primary endpoint was the change in ankle circumference from baseline to day 90. Secondary endpoints included patient-reported symptoms assessed by visual analogue scales for pain, heaviness/warmth, itching, nocturnal cramps, self-perceived edema/swelling, visible varicosity, and self-perceived quality of life.
Of the 60 enrolled patients, 40 completed the study, corresponding to a 33.3% drop-out/non-completer rate (20/60). Eight patients were lost to follow-up and 12 did not consistently take the tested product (adherence <70%). This high drop-out rate substantially limits the statistical analysis and the value of the final outcomes. In the completer population, mean ankle circumference significantly decreased from 23.1±1.8 cm at baseline to 21.4±1.4 cm at Day 90, corresponding to a mean reduction of 1.7±0.5 cm (p=0.023). Significant improvements were also observed in all subjective parameters except visible varicosity, with benefits already detectable at Day 45 and maintained or enhanced at Day 90. No adverse events leading to treatment discontinuation were reported.
In this real-world cohort of patients with symptoms suggestive of early chronic venous disease, the tested nutraceutical combination was associated with significant improvements in both objective and subjective outcomes and was well tolerated. However, given the uncontrolled observational design and the 33.3% drop-out/non-completer rate, these findings should be considered preliminary and not definitive evidence of a causal treatment effect.
Downloads
1.De Maeseneer MG, Kakkos SK, Aherne T, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg 2022;63:184-267. DOI: https://doi.org/10.1016/j.ejvs.2022.06.022
2.Kienzl P, Deinsberger J, Weber B. Chronic venous disease: pathophysiological aspects, risk factors, and diagnosis. Hamostaseologie 2024;44:277-86. DOI: https://doi.org/10.1055/a-2315-6206
3.Rabe E, Blanc-Guillemaud V, Onselaer MB, et al. Reduction of lower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: a systematic literature review and meta-analysis. Int Angiol 2023;42:488-502. DOI: https://doi.org/10.23736/S0392-9590.23.05084-8
4.Robertson LA, Lee AJ, Evans CJ, et al. Incidence of chronic venous disease in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord 2013;1:59-67. DOI: https://doi.org/10.1016/j.jvsv.2012.05.006
5.Ortega MA, Fraile-Martínez O, García-Montero C, et al. Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. J Clin Med 2021;10:3239. DOI: https://doi.org/10.3390/jcm10153239
6.Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord 2020;8:342-52. DOI: https://doi.org/10.1016/j.jvsv.2019.12.075
7.Santiago FR, Ulloa J, Régnier C, et al. The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives. J Comp Eff Res 2022;11:789-803. DOI: https://doi.org/10.2217/cer-2022-0054
8.Patel SK, Surowiec SM. Venous insufficiency. 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430975/
9.Mostafa RE, Ali DE, El-Shiekh RA, et al. Therapeutic applications of natural products in the management of venous diseases: a comprehensive review. Inflammopharmacology 2025;33:1673-712. DOI: https://doi.org/10.1007/s10787-025-01688-z
10.Buso G, Santini P, Ghirardini F, et al. The role of bromelain and liposomal vitamin C in the treatment of chronic venous disease. Vasa 2025;54:164-76. DOI: https://doi.org/10.1024/0301-1526/a001184
11.Guven H. Effect of micronized purified flavonoid fraction on venous hemodynamics evaluated using digital photoplethysmography in patients with chronic venous disease. Ann Vasc Surg 2024;109:284-90. DOI: https://doi.org/10.1016/j.avsg.2024.06.015
12.Greco M, Bissacco D. Improving venous symptoms in C0s-C1s patients after multicomponent diosmin-based preparation: Initial experience. Phlebology 2023;38:348-51. DOI: https://doi.org/10.1177/02683555231169088
13.Serra R, Ielapi N, Bitonti A, et al. Efficacy of a low-dose diosmin therapy on improving symptoms and quality of life in patients with chronic venous disease: randomized, double-blind, placebo-controlled trial. Nutrients 2021;13:999. DOI: https://doi.org/10.3390/nu13030999
14.Russo R, Chandradhara D, De Tommasi N. Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers. Molecules 2018;23:2174. DOI: https://doi.org/10.3390/molecules23092174
15.Russo R, Mancinelli A, Ciccone M, et al. Pharmacokinetic profile of μsMIN Plus, a new micronized diosmin formulation, after oral administration in rats. Nat Prod Commun 2015;10:1569-72. DOI: https://doi.org/10.1177/1934578X1501000921
16.Safayhi H, Boden SE, Schweizer S, Ammon HPT. Concentration-dependent potentiating and inhibitory effects of Boswellia extracts on 5-lipoxygenase product formation in stimulated PMNL. Planta Med 2000;66:110-3. DOI: https://doi.org/10.1055/s-2000-11136
17.Poeckel D, Tausch L, Altmann A, et al. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid. Br J Pharmacol 2005;146:514-24. DOI: https://doi.org/10.1038/sj.bjp.0706366
18.Singh S, Khajuria A, Taneja SC, et al. Boswellic acids: a leukotriene inhibitor also effective through topical application in inflammatory disorders. Phytomedicine 2008;15:400-7. DOI: https://doi.org/10.1016/j.phymed.2007.11.019
19.Gupta OP, Sharma N, Chand D. A sensitive and relevant model for evaluating anti-inflammatory activity-papaya latex-induced rat paw inflammation. J Pharmacol Toxicol Methods 1992;28:15-9. DOI: https://doi.org/10.1016/1056-8719(92)90060-E
20.Pungle P, Banavalikar M, Suthar A, et al. Immunomodulatory activity of boswellic acids of Boswellia serrata Roxb. Indian J Exp Biol 2003;41:1460-2.
21.Ammon HPT. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine 2010;17:862-7. DOI: https://doi.org/10.1016/j.phymed.2010.03.003
22.Roy S, Khanna S, Krishnaraju AV, et al. Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. Antioxid Redox Signal 2006;8:653-60. DOI: https://doi.org/10.1089/ars.2006.8.653
23.Cavezzi A, Urso SU, Ambrosini L, et al. Lymphedema and nutrition: a review. Veins and Lymphatics 2019;8:8220. DOI: https://doi.org/10.4081/vl.2019.8220
24.Leelakanok N, Petchsomrit A, Janurai T, et al. Efficacy and safety of bromelain: a systematic review and meta-analysis. Nutr Health 2023;29:479-503. DOI: https://doi.org/10.1177/02601060231173732
25.Gylling U, Rintala A, Taipale S, Tammisto T. The effect of a proteolytic enzyme combinate (bromelain) on the postoperative oedema by oral application: a clinical and experimental study. Acta Chir Scand 1966;131:193-6.
26.Kumakura S, Kamo I, Tsurufuji S. Role of bradykinin in the vascular permeability response induced by carrageenin in rats. Br J Pharmacol 1988;93:739-46. DOI: https://doi.org/10.1111/j.1476-5381.1988.tb11457.x
27.Hale LP, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol 1992;149:3809-16. DOI: https://doi.org/10.4049/jimmunol.149.12.3809
28.Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol 2008;128:66-74. DOI: https://doi.org/10.1016/j.clim.2008.02.015
29.Gläser D, Hilberg T. The influence of bromelain on platelet count and platelet activity in vitro. Platelets 2006;17:37-41. DOI: https://doi.org/10.1080/09537100500197489
CRediT authorship contribution
AFGC designed and carried out the tests, analysed the data and wrote the paper.
Data Availability Statement
The data are not yet included in a repository, but are available upon specific request.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
